- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
April 23, 2024David Martinez Recognized Among Top 100 Lawyers in Los Angeles by LA Business Journal
-
April 15, 2024Robins Kaplan Named to 2024 BTI Client Service A-Team
-
April 9, 2024Robins Kaplan LLP Files Complaint Against Social Media Giants Meta, Snap, TikTok on Behalf of Spirit Lake Nation, Menominee Indian Tribe of Wisconsin
-
April 30, 2024Navigating Generational Dynamics
-
May 2-3, 2024ACI Advanced Forum on Managed Care Disputes and Litigation
-
May 6, 2024Litigating with the Legends
-
First QuarterGENERICally Speaking: A Hatch-Waxman Litigation Bulletin
-
March 2024e-Commerce: Pitfalls and Protections
-
March 25, 2024Endo Ventures Unlimited Co. v. Nexus Pharms. Inc.
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
GENERICally Speaking Hatch Waxman Bulletin
The Hatch-Waxman Litigation practice group at Robins Kaplan LLP is pleased to offer the latest edition of their quarterly publication regarding ANDA patent litigation issues and the generics business.
GENERICally Speaking: A Hatch-Waxman Litigation Bulletin - Q4
The Winter 2021 issue of the GENERICally Speaking email campaign provides you and your company with some of the knowledge beneficial to remaining attentive to the complexity of ANDA patent litigation.
In this issue:
- AstraZeneca AB v. Mylan Pharms., Inc.
Symbicort® (formoterol/budesonide)
The appellate court reversed the district court’s claim construction and vacated and remanded its finding of infringement, but affirmed the district court’s determination that the patents-in-suit were not invalid as obvious. - Biogen Int’l GMBH v. Mylan Pharms. Inc.
Tecfidera® (dimethyl fumarate)
The Federal Circuit held that the district court did not clearly err in determining that the asserted claims were invalid for lack of written description. - Horizon Medicines LLC v. Alkem Labs. Ltd.
Duexis® (ibuprofen/famoditine)
Federal Circuit affirmed district court’s findings that asserted claims of one patent-in-suit are invalid as obvious and that the asserted claims of a second patent-in-suit are not infringed by Defendant’s ANDA. - Celgene Corp. v. Mylan Pharms., Inc.
Pomalyst® (pomalidomide)
Because Mylan did not have a regular and established place of business in NJ, the Federal Circuit affirmed the district court’s dismissal of the underlying action for lack of person jurisdiction. - Association for Accessible Medicines v. Bonta
N/A
Because California’s AB 824—which presumed branded-generic patent litigation settlements were anticompetitive—likely violated the dormant Commerce Clause and likely irreparably harmed Plaintiff association’s members, the court granted Plaintiff’s motion for preliminary injunction. - Janssen Pharms., Inc. v. Teva Pharms. USA, Inc.
Invega Sustenna® (paliperidone palmitate)
Defendant did not prove by clear and convincing evidence that the asserted claims were obvious, indefinite, or lacking an adequate written description. - Melinta Therapeutics, LLC v. Nexus Pharms., Inc.
Minocin® (minocycline HCl)
The court denied defendant’s Rule 12(b)(3) motion to dismiss and granting defendant’s motion to transfer venue to the Northern District of Illinois. - Jazz Pharms., Inc. v. Avadel Pharms. Plc
Xyrem® (sodium oxybate)
The court found that there were questions of fact as to whether Plaintiff was required to list the ’963 patent in the Orange Book, and that precluded entry of judgment on the pleadings. - AstraZeneca AB v. Zydus Pharms. (USA) Inc.
Farxiga® (dapagliflozin)
Because the main piece of prior art did not identify a lead compound for further development and other references taught away from the claimed invention, the asserted claims were held not invalid. - Bausch Health Ireland Ltd. v. Padagis Israel Pharms. Ltd.
Bryhali® (halobetasol propionate)
Defendant’s motion to amend to include affirmative defense and counterclaim of inequitable conduct was granted when applicants failed to disclose relevant clinical study data and prior art saying the opposite of declaration submitted during prosecution and in support of invention. - H. Lundbeck A/S v. Lupin Ltd.
Trintellix® (vortioxetine hydrobromide)
Defendants failed to invalidate all of the patents-in-suit, but Plaintiffs failed to prove that Defendants’ ANDA products, with one exception, would infringe the asserted claims.
Relevant ANDA Updates highlighted in this issue:
Related Professionals
Christopher A. Pinahs
Partner
Reported settlements in federal district court cases
Federal district court cases that are filed pursuant to the Hatch-Waxman Act
New Drug Applications and 505(b)(2) Applications
Abbreviated New Drug Applications and 505(b)(2) Applications
N/A
Symbicort® (formoterol/budesonide)
Duexis® (ibuprofen/famoditine)
Invega Sustenna® (paliperidone palmitate)
Pomalyst® (pomalidomide)
Minocin® (minocycline HCl)
Xyrem® (sodium oxybate)
Farxiga® (dapagliflozin)
Bryhali® (halobetasol propionate)
Tecfidera® (dimethyl fumarate)
Trintellix® (vortioxetine hydrobromide)
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.